{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:18:40Z","timestamp":1766168320311,"version":"3.48.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014822","name":"The Notsew Orm Sands Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jctube.2025.100569","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:03:45Z","timestamp":1760807025000},"page":"100569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The synergy of therapeutic vaccination and timely diagnosis for TB control in high-burden settings: Nunavut as a case study"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-3357","authenticated-orcid":false,"given":"Elaheh","family":"Abdollahi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0227","authenticated-orcid":false,"given":"Seyed M.","family":"Moghadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison P.","family":"Galvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2025.100569_b0005","unstructured":"WHO. Tuberculosis(TB) n.d. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis (accessed May 11, 2021)."},{"key":"10.1016\/j.jctube.2025.100569_b0010","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1473-3099(23)00372-9","article-title":"Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews","volume":"23","author":"Litvinjenko","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jctube.2025.100569_b0015","unstructured":"Canada PHA of. Tuberculosis in Canada: 2012 to 2021 expanded report 2024. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/tuberculosis-canada-expanded-report-2012-2021.html (accessed September 4, 2025)."},{"key":"10.1016\/j.jctube.2025.100569_b0020","unstructured":"WHO | The End TB Strategy. WHO n.d. http:\/\/www.who.int\/tb\/strategy\/en\/ (accessed May 11, 2021)."},{"key":"10.1016\/j.jctube.2025.100569_b0025","unstructured":"WHO. Global tuberculosis report 2021 n.d. https:\/\/www.who.int\/publications-detail-redirect\/9789240037021 (accessed September 30, 2022)."},{"key":"10.1016\/j.jctube.2025.100569_b0030","unstructured":"Canada IS. Eliminating Tuberculosis across Inuit Nunangat by 2030; at least a 50% reduction by 2025 2018. https:\/\/www.canada.ca\/en\/indigenous-services-canada\/news\/2018\/03\/eliminating-tuberculosis-across-inuit-nunangat-by-2030-at-least-a-50-reduction-by-2025.html (accessed September 5, 2025)."},{"key":"10.1016\/j.jctube.2025.100569_b0035","unstructured":"Filliter E. Inuit Tuberculosis Elimination Framework. Inuit Tapiriit Kanatami 2018. https:\/\/www.itk.ca\/inuittbeliminationframework\/ (accessed May 11, 2021)."},{"key":"10.1016\/j.jctube.2025.100569_b0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.idm.2022.07.005","article-title":"Evaluation of TB elimination strategies in Canadian Inuit populations: nunavut as a case study","volume":"7","author":"Abdollahi","year":"2022","journal-title":"Infectious Disease Model"},{"key":"10.1016\/j.jctube.2025.100569_b0045","unstructured":"TB Vaccine Clinical Pipeline. Working Group on New TB Vaccines n.d. https:\/\/newtbvaccines.org\/tb-vaccine-pipeline\/clinical-phase\/ (accessed September 5, 2025)."},{"key":"10.1016\/j.jctube.2025.100569_b0050","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","article-title":"WHO preferred product characteristics for new vaccines against tuberculosis","volume":"18","author":"Schrager","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jctube.2025.100569_b0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vaccine.2019.10.072","article-title":"Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: key considerations from World Health Organization consultations","volume":"38","author":"Vekemans","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jctube.2025.100569_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00045-1","article-title":"The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study","volume":"11","author":"Clark","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jctube.2025.100569_b0065","unstructured":"Government of Canada SC. 2016 Census Topic: Age and sex 2017. https:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/rt-td\/as-eng.cfm (accessed May 7, 2022)."},{"key":"10.1016\/j.jctube.2025.100569_b0070","unstructured":"Government of Canada SC. Census Profile, 2016 Census - Nunavut [Territory] and Canada [Country] 2017. https:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/dp-pd\/prof\/details\/Page.cfm?Lang=E&Geo1=PR&Code1=62&Geo2=&Code2=&SearchText=Nunavut&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=62&type=0 (accessed April 24, 2021)."},{"key":"10.1016\/j.jctube.2025.100569_b0075","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1186\/s12889-022-13402-7","article-title":"Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study","volume":"22","author":"Drolet","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jctube.2025.100569_b0080","article-title":"The impact of contact patterns on epidemic dynamics","volume":"12","author":"Yin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jctube.2025.100569_b0085","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jctube.2025.100569_b0090","unstructured":"Government of Canada SC. Life expectancy and other elements of the abridged life table, three-year estimates, Prince Edward Island and the territories 2022. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310014001 (accessed April 15, 2022)."},{"key":"10.1016\/j.jctube.2025.100569_b0095","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/ije\/dyr058","article-title":"The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach","volume":"40","author":"Borgdorff","year":"2011","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jctube.2025.100569_b0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/spid.2001.22785","article-title":"Transmission of mycobacterium tuberculosis to and from children and adolescents","volume":"12","author":"Starke","year":"2001","journal-title":"Semin Pediatr Infect Dis"},{"key":"10.1016\/j.jctube.2025.100569_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248493","article-title":"Individual and public health consequences associated with a missed diagnosis of pulmonary tuberculosis in the emergency department: a retrospective cohort study","volume":"16","author":"Heffernan","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jctube.2025.100569_b0110","unstructured":"Canada PHA of. Chapter6: Canadian Tuberculosis Standards 7th Edition: 2014 \u2013 Dick Menzies, MD, MSc, Gonzalo G. Alvarez, MD MPH, FRCPC, Kamran Khan, MD MPH, FRCPC. Aem 2014. https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/canadian-tuberculosis-standards-7th-edition\/edition-18.html#s5-1 (accessed April 25, 2021)."},{"key":"10.1016\/j.jctube.2025.100569_b0115","unstructured":"Canada PHA of. Chapter12: Canadian Tuberculosis Standards 7th Edition: 2014 \u2013 Contact follow-up and outbreak management in Tuberculosis control. Aem 2014. https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/canadian-tuberculosis-standards-7th-edition\/edition-8.html (accessed April 25, 2021)."},{"key":"10.1016\/j.jctube.2025.100569_b0120","unstructured":"Canada PHA of. Chapter5: Canadian Tuberculosis Standards 7th Edition: 2014 \u2013 Treatment of Tuberculosis disease 2014. https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/canadian-tuberculosis-standards-7th-edition\/edition-17.html (accessed May 7, 2022)."},{"key":"10.1016\/j.jctube.2025.100569_b0125","article-title":"How long are TB patients infectious?","volume":"163","author":"Ahmad","year":"2000","journal-title":"CMAJ"},{"key":"10.1016\/j.jctube.2025.100569_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000146","article-title":"Effect of duration and intermittency of Rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis","volume":"6","author":"Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jctube.2025.100569_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012306","article-title":"Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study","volume":"8","author":"Mao","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.jctube.2025.100569_b0140","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jiy265","article-title":"Risk and timing of tuberculosis among close contacts of persons with infectious tuberculosis","volume":"218","author":"Reichler","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jctube.2025.100569_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020755","article-title":"Assessing tuberculosis case fatality ratio: a meta-analysis","volume":"6","author":"Straetemans","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jctube.2025.100569_b0150","article-title":"Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis","volume":"14","author":"Torres","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jctube.2025.100569_b0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell\u2013based assays for the diagnosis of latent tuberculosis infection: an update","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jctube.2025.100569_b0160","unstructured":"Canada PHA of. Publications: Diseases and conditions 2015. https:\/\/www.canada.ca\/en\/services\/health\/publications\/diseases-conditions.html (accessed September 5, 2025)."},{"key":"10.1016\/j.jctube.2025.100569_b0165","unstructured":"Obtaining a Research License under Nunavut\u2019s Scientists Act: A Guide for Applicants 2021."},{"key":"10.1016\/j.jctube.2025.100569_b0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3934\/mbe.2017039","article-title":"Mixed vaccination strategy for the control of tuberculosis: a case study in China","volume":"14","author":"Liu","year":"2017","journal-title":"Math Biosci Eng"},{"key":"10.1016\/j.jctube.2025.100569_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2020.110490","article-title":"A structured Markov chain model to investigate the effects of pre-exposure vaccines in tuberculosis control","volume":"509","author":"Fern\u00e1ndez-Peralta","year":"2021","journal-title":"J Theor Biol"},{"key":"10.1016\/j.jctube.2025.100569_b0180","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3201\/eid1009.030921","article-title":"Potential public health impact of new tuberculosis vaccines","volume":"10","author":"Ziv","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jctube.2025.100569_b0185","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"PNAS"},{"key":"10.1016\/j.jctube.2025.100569_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtbi.2019.02.020","article-title":"Evaluating vaccination strategies for tuberculosis in endemic and non-endemic settings","volume":"469","author":"Renardy","year":"2019","journal-title":"J Theor Biol"},{"key":"10.1016\/j.jctube.2025.100569_b0195","unstructured":"Tobacco Facts. Nunavut Quits} 2019. https:\/\/nuquits.gov.nu.ca\/tobacco-facts (accessed September 5, 2025)."},{"key":"10.1016\/j.jctube.2025.100569_b0200","first-page":"392","article-title":"The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era","volume":"8","author":"Marais","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jctube.2025.100569_b0205","first-page":"401","article-title":"Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis","volume":"111","author":"Mart\u00ednez Alfaro","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jctube.2025.100569_b0210","doi-asserted-by":"crossref","unstructured":"Alvarez GG, Van Dyk D, Mallick R, Lesperance S, Demaio P, Finn S, et al. The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study. Int J Circumpolar Health n.d.;79:1758501. https:\/\/doi.org\/10.1080\/22423982.2020.1758501.","DOI":"10.1080\/22423982.2020.1758501"},{"issue":"2","key":"10.1016\/j.jctube.2025.100569_b0215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/aje\/kwad185","article-title":"Examining the influence of imbalanced social contact matrices in epidemic models","volume":"193","author":"Hamilton","year":"2024","journal-title":"Am J Epidemiol"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579425000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579425000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:15:55Z","timestamp":1766168155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579425000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"alternative-id":["S2405579425000609"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2025.100569","relation":{},"ISSN":["2405-5794"],"issn-type":[{"type":"print","value":"2405-5794"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The synergy of therapeutic vaccination and timely diagnosis for TB control in high-burden settings: Nunavut as a case study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2025.100569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100569"}}